Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Biopolymers|December 17, 2020
Diffusion coefficients for rigid macromolecules with irregular shapes that allow rotational-translational couplingWilliam A Wegener
Leukemia & Lymphoma|March 11, 2010
Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospectsDavid M Goldenberg, Franck Morschhauser, William A Wegener
Arthritis Research & Therapy|April 25, 2006
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosusThomas Dörner, Joerg Kaufmann, William A Wegener, et al.
Cancer|October 15, 2008
Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphomaJohn P Leonard, Stephen J Schuster, Christos Emmanouilides, et al.
Arthritis Research & Therapy|July 25, 2006
Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II studySerge D Steinfeld, Laure Tant, Gerd R Burmester, et al.
British Journal of Haematology|July 9, 2013
Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I studyHoward A Liebman, Mansoor N Saleh, James B Bussel, et al.
Haematologica|August 13, 2016
Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopeniaHoward A Liebman, Mansoor N Saleh, James B Bussel, et al.
Journal of Pediatric Surgery|September 11, 2004
Diagnosing suspected acute nonclassic appendicitis with sulesomab, a radiolabeled antigranulocyte antibody imaging agentAnthony M Passalaqua, Robert L Klein, William A Wegener, et al.
Cancer|February 4, 2010
Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapyLudovic Ferrer, Françoise Kraeber-Bodéré, Caroline Bodet-Milin, et al.
JAMA Dermatology|August 19, 2014
Subcutaneous veltuzumab, a humanized anti-CD20 antibody, in the treatment of refractory pemphigus vulgarisChristoph T Ellebrecht, Eun J Choi, David M Allman, et al.
Pageof 5